Janus激酶(JAK)抑制剂已成为治疗多种免疫介导疾病的新型药物。然而,关于安全问题对其使用和处方实践的影响,存在有限的洞察力。因此,这项研究的目的是描述JAK抑制剂在加拿大的应用,在全国范围内和个别省份内。我们使用了IQVIA的Compuscript数据库中的数据。我们对零售药店分配的所有JAK抑制剂单位进行了重复的横断面研究(托法替尼,鲁索替尼,baricitinib,和upadacitinib)从2016年7月1日至2022年6月30日在加拿大十个省份内。在整个加拿大,在2016年至2022年期间,门诊药房分配的JAK抑制剂单位估计为26,126,409单位,平均每100,000人分配9,431单位.随着时间的推移,所有省份的JAK抑制剂单位分配率都在增加,在2021年7月至2022年6月之间,新不伦瑞克省表现出最高的比率(每100,000人中有27,696台),爱德华王子岛的费率最低(每100,000个10,065个单位)。在这项研究中,在研究期间,加拿大JAK抑制剂的利用率有所增加,在省和国家层面都很明显。各省之间JAK抑制剂使用的差异强调了进一步调查以确定适当使用方法的必要性。要点•从2016年到2022年,加拿大各地的零售药店估计总共发放了26,126,409个JAK抑制剂单位,人口中每10万人平均发放9,431个单位。•Tofacitinib是在整个研究期间分配最多的JAK抑制剂,占所有发放单位的76%。鲁索替尼,upadacitinib,Baricitinib占16%,7.9%,和1.1%的JAK抑制剂单位分配,分别。•加拿大各省采用JAK抑制剂的差异可能受到几个因素的影响,包括药物覆盖范围,疾病患病率,和医生开处方的模式。
Janus Kinase (JAK) inhibitors have emerged as a novel category of medications to treat a variety of immune-mediated conditions. However, limited insight exists regarding the impact of safety concerns on their usage and prescribing practices. Therefore, the objective of this study was to describe the utilization of JAK-inhibitors in Canada, both nationally and within individual provinces. We used data from IQVIA\'s Compuscript database. We conducted a repeated cross-sectional study of all JAK-inhibitor units dispensed in retail pharmacies (tofacitinib, ruxolitinib, baricitinib, and upadacitinib) within the ten Canadian provinces from July 1, 2016, to June 30, 2022. Throughout Canada, outpatient pharmacies dispensed an estimated total of 26,126,409 JAK-inhibitor units between 2016 and 2022, averaging 9,431 units dispensed per 100,000 population. All provinces had increasing rates of JAK-inhibitor units dispensed over time, whereby between July 2021 to June 2022, New Brunswick exhibited the highest rates (27,696 units per 100,000), and Prince Edward Island demonstrated the lowest rates (10,065 units per 100,000). In this study, utilization of JAK-inhibitors increased in Canada over the study period, evident at both provincial and national levels. Variability in JAK-inhibitor utilization between provinces underscores the necessity for further investigations to ascertain appropriate usage practices. Key Points • From 2016 to 2022, an estimated total of 26,126,409 JAK-inhibitor units were dispensed in retail pharmacies across Canada, with an average rate of 9,431 units dispensed for every 100,000 people in the population. • Tofacitinib was the most dispensed JAK-inhibitor during the entire study period, making up 76% of all units dispensed. Ruxolitinib, upadacitinib, and baricitinib made up 16%, 7.9%, and 1.1% of the JAK-inhibitor units dispensed, respectively. • The variance in provincial adoption of JAK-inhibitors across Canada might be influenced by several factors, including drug coverage availability, disease prevalence, and physician prescribing patterns.